文献速递妇科产科

辅助治疗对手术分期2009 FIGO I期子宫浆液性癌生存的影响

Impact of adjuvant treatment on survival in surgically staged 2009 FIGO stage I uterine serous carcinoma.
PubMed 文献 · Gynecol Oncol · 2026-10-15

该回顾性研究纳入327例2009 FIGO I期子宫浆液性癌手术患者,按肌层浸润深度分层。肌层浸润者辅助化疗与5年OS改善相关(79.9% vs 52.3%,P=0.008),无肌层浸润者未见生存获益;无肌层浸润且腹膜细胞学阳性者预后与肌层浸润者相似,5年PFS仅48.8%。

要点

  • 肌层浸润患者辅助化疗独立改善PFS(aHR 0.50)和OS(aHR 0.42)。
  • 无肌层浸润者辅助化疗未见生存获益。
  • 无肌层浸润但细胞学阳性者5年PFS为48.8%,预后差。

核心结论

  • 肌层浸润的I期子宫浆液性癌患者术后辅助化疗与生存改善相关,无肌层浸润者未见获益。
  • 恶性腹膜细胞学在无肌层浸润患者中具有强预后价值,其结局与肌层浸润肿瘤相似。
  • 研究支持将细胞学状态纳入I期子宫浆液性癌的辅助治疗决策。

研究设计与样本

  • 单机构回顾性研究,纳入327例新诊断2009 FIGO I期子宫浆液性癌手术患者。
  • 按肌层浸润深度分层:无肌层浸润185例(56.6%),<50%浸润113例(34.6%),≥50%浸润29例(8.9%)。

主要发现

  • 肌层浸润患者中,化疗组与未化疗组的5年PFS分别为62.6%(95%CI 52.2%-71.3%)和54.4%(95%CI 35%-70.2%),P=0.10。
  • 肌层浸润患者中,化疗组与未化疗组的5年OS分别为79.9%(95%CI 70.4%-86.6%)和52.3%(95%CI 33.4%-68.2%),P=0.008。
  • 化疗与改善PFS独立相关(aHR 0.50,95%CI 0.26-0.96)和改善OS独立相关(aHR 0.42,95%CI 0.23-0.78)。
  • 无肌层浸润且细胞学阴性者5年PFS为89.5%(95%CI 83.4%-93.5%),细胞学阳性者为48.8%(95%CI 22.8%-70.6%;HR 0.19,95%CI 0.08-0.44)。

临床怎么用

  • 对I期子宫浆液性癌伴肌层浸润者,术后可考虑辅助化疗以改善生存。
  • 对无肌层浸润者,辅助化疗决策需结合腹膜细胞学状态,细胞学阳性者预后差,可参考肌层浸润者的治疗策略。

局限性

  • 回顾性单中心研究,存在选择偏倚可能。
  • 无肌层浸润且细胞学阳性亚组样本量小,结论需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the impact of adjuvant chemotherapy on oncologic outcomes in patients with surgically staged 2009 FIGO stage I uterine serous carcinoma (USC) and to assess the prognostic significance of peritoneal cytology. METHODS: We retrospectively reviewed patients who underwent surgery at our institution for newly diagnosed, 2009 FIGO stage I USC. Outcomes were stratified by depth of myometrial invasion. RESULTS: We identified 327 patients: 185 (56.6%) with non-myoinvasive disease, 113 (34.6%) with <50% myometrial invasion, and 29 (8.9%) with ≥50% myometrial invasion. Among patients with any myoinvasion, the 5-year PFS was 54.4% (95% CI: 35%-70.2%) for no chemotherapy versus 62.6% (95% CI: 52.2%-71.3%) for chemotherapy (P = 0.10), and the 5-year OS was 52.3% (95% CI: 33.4%-68.2%) versus 79.9% (95% CI: 70.4%-86.6%), respectively (P = 0.008). Use of chemotherapy was independently associated with improved PFS (adjusted HR, 0.50 [95% CI: 0.26-0.96]) and OS (adjusted HR, 0.42 [95% CI: 0.23-0.78]). For patients with non-myoinvasive disease and negative cytology, the 5-year PFS was 89.5% (95% CI: 83.4%-93.5%), and for those with positive cytology, it was 48.8% (95% CI: 22.8%-70.6%; HR, 0.19 [95% CI: 0.08-0.44]). CONCLUSIONS: In this patient cohort, postoperative adjuvant chemotherapy was associated with improved survival when myoinvasion was present but did not appear to confer a survival benefit in the absence of myoinvasion. Malignant peritoneal cytology was strongly prognostic in non-myoinvasive disease, and these patients had outcomes resembling those with myoinvasive tumors. These findings support incorporating cytology status into adjuvant decision-making for stage I USC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Graves SM, Yoh K, Sia TY, et al. Impact of adjuvant treatment on survival in surgically staged 2009 FIGO stage I uterine serous carcinoma. Gynecol Oncol. 2026. PMID: 42880204. doi:10.1016/j.ygyno.2026.10.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。